Concurrent EGFR-TKI and Thoracic Radiotherapy as First-Line Treatment for Stage IV Non-Small Cell Lung Cancer Harboring EGFR Active Mutations

肿瘤科 医学 阶段(地层学) 肺癌 放射治疗 内科学 表皮生长因子受体抑制剂 表皮生长因子受体 癌症研究 癌症 生物 古生物学
作者
Linpeng Zheng,Yanmei Wang,Zihan Xu,Qiao Yang,Guangkuo Zhu,Xingyun Liao,Xiewan Chen,Bo Zhu,Yu‐zhong Duan,Jianguo Sun
出处
期刊:Oncologist [AlphaMed Press]
卷期号:24 (8): 1031-e612 被引量:77
标识
DOI:10.1634/theoncologist.2019-0285
摘要

LESSONS LEARNED: This single-arm, phase II study shows that concurrent EGFR-tyrosine kinase inhibitor plus thoracic radiotherapy as the first-line treatment for stage IV non-small cell lung cancer harboring EGFR active mutations provides long-term control for the primary lung lesion, and 1-year progression-free survival (PFS) rate and median PFS are numerically higher than those of the erlotinib monotherapy.Serious adverse events are acceptable, although grade >3 radiation pneumonitis occurred in 20% of patients. BACKGROUND: Studies show effective local control by EGFR-tyrosine kinase inhibitor (TKI) combined with radiotherapy at metastatic sites in advanced lung cancer harboring EGFR active mutations. Salvage local radiotherapy is associated with prolonged progression-free survival (PFS) in local disease during EGFR-TKI treatment. However, no prospective study has been reported on concurrent EGFR-TKI and radiotherapy for primary lung lesions. This study investigated the efficacy and safety of first-line EGFR-TKI combined with thoracic radiotherapy in treating stage IV non-small cell lung cancer (NSCLC) harboring EGFR active mutations. METHODS: We conducted a single-arm, phase II clinical trial. Each patient received EGFR-TKI (erlotinib 150 mg or gefitinib 250 mg per day) plus thoracic radiotherapy (54-60 Gy/27-30 F/5.5-6 w) within 2 weeks of beginning EGFR-TKI therapy until either disease progression or intolerable adverse events (AEs) appeared. RESULTS: From January 2015 to March 2018, 401 patients were screened, and 10 patients (5 male and 5 female) were eligible. These patients had a median age of 55 years (40-75) and median follow-up of 19.8 months (5.8-34). The 1-year PFS rate was 57.1%, median PFS was 13 months, and median time to progression of irradiated lesion (iTTP) was 20.5 months. Objective response rate (ORR), was 50% and disease control rate (DCR) was 100%. The most common grade ≥3 AEs were radiation pneumonitis (20%) and rash (10%). One patient died after rejecting treatment for pneumonitis. The others received a full, systematic course of glucocorticoid therapy. Pneumonitis was all well controlled and did not relapse. CONCLUSION: Concurrent EGFR-TKI plus thoracic radiotherapy as the first-line treatment for stage IV NSCLC harboring EGFR active mutations shows a long-term control of primary lung lesion. The 1-year PFS rate and median PFS of this combined therapy are numerically higher than those of the erlotinib monotherapy. The risk of serious adverse events is acceptable.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
syyy完成签到,获得积分10
刚刚
刚刚
ssc完成签到,获得积分10
1秒前
mmol发布了新的文献求助10
1秒前
null完成签到,获得积分0
1秒前
风趣忻发布了新的文献求助10
1秒前
赘婿的应助被流苏采纳,获得10
2秒前
daddadadada完成签到 ,获得积分10
2秒前
阳光的半雪完成签到,获得积分10
2秒前
胖三斤完成签到,获得积分10
2秒前
nyh完成签到 ,获得积分10
2秒前
桃桃发布了新的文献求助10
2秒前
噫吁嚱发布了新的文献求助10
3秒前
3秒前
3秒前
3秒前
wyyyy发布了新的文献求助10
4秒前
宋紫馨发布了新的文献求助10
4秒前
leye完成签到,获得积分20
5秒前
5秒前
lulu完成签到 ,获得积分10
6秒前
yyy完成签到,获得积分10
6秒前
再吃一颗苹果完成签到,获得积分10
7秒前
如意听安发布了新的文献求助10
7秒前
null发布了新的文献求助10
7秒前
8秒前
Iris完成签到,获得积分20
8秒前
一柯完成签到,获得积分20
9秒前
9秒前
沉静的清涟完成签到,获得积分10
9秒前
科研通AI6.4的应助被想喝奶茶采纳,获得10
10秒前
Orange的应助被科研通管家采纳,获得10
10秒前
勤奋一一的应助被科研通管家采纳,获得10
10秒前
田様的应助被科研通管家采纳,获得10
10秒前
zhonglv7的应助被科研通管家采纳,获得10
10秒前
CodeCraft的应助被科研通管家采纳,获得10
10秒前
所所的应助被七安采纳,获得10
10秒前
无花果的应助被科研通管家采纳,获得10
10秒前
星辰大海的应助被科研通管家采纳,获得10
10秒前
充电宝的应助被愉快数据线采纳,获得10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8182102
求助须知:如何正确求助?哪些是违规求助? 9571775
关于积分的说明 21819723
捐赠科研通 7778500
什么是DOI,文献DOI怎么找? 3433617
关于科研通互助平台的介绍 2557786
邀请新用户注册赠送积分活动 2479651